Working… Menu
Trial record 79 of 228 for:    EDN1

Propofol Cardioprotection for Type II Diabetics

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00734383
Recruitment Status : Completed
First Posted : August 14, 2008
Last Update Posted : July 13, 2012
Canadian Institutes of Health Research (CIHR)
Information provided by (Responsible Party):
University of British Columbia

Brief Summary:
The purpose of this study is to determine if an intravenous anesthetic with antioxidant properties will protect the heart of diabetic patients from injury while undergoing coronary bypass surgery.

Condition or disease Intervention/treatment Phase
Myocardial Injury Drug: Propofol Phase 2 Phase 3

  Show Detailed Description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 137 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: PRO-TECT II: Propofol Cardioprotection for Type II Diabetics
Study Start Date : April 2005
Actual Primary Completion Date : May 2012
Actual Study Completion Date : June 2012

Resource links provided by the National Library of Medicine

Drug Information available for: Propofol

Arm Intervention/treatment
Experimental: 1
Propofol Cardioprotection
Drug: Propofol
Propofol cardioprotection : Ten minutes prior to initiation of CPB, we will stop delivery of isoflurane, inject 1 mg/kg iv and then continuously infuse propofol at 120µg/kg/min IV until 15 min after release of the aortic cross clamp (reperfusion).

Experimental: 2
Volatile Anesthesia Preconditioning
Drug: Propofol
Volatile Anesthetic preconditioning : Anesthesia will be maintained using an inspired concentration of isoflurane between 0.5-2% before, during, and after CPB, without administration of propofol. For ten minutes prior to the initiation of CPB we will deliver Isoflurane 2.5% end tidal then resume maintenance anesthesia as described.

Primary Outcome Measures :
  1. Perioperative Plasma 15 f2t isoprostane, a biologically active marker of oxidative stress [ Time Frame: 24 hours post operation ]

Secondary Outcome Measures :
  1. Perioperative (includes coronary sinus levels) plasma antioxidant concentration; ET-1, TNF alpha, Troponin I, peroxynitrite; gene and protein expression of eNOS and iNOS; hemodynamics [ Time Frame: 24 hours post operation ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   19 Years to 29 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients with and without Type II Diabetes Mellitus
  2. Hemodynamically Stable
  3. Non urgent Coronary Bypass Grafting utilizing Cardiopulmonary Bypass

Exclusion Criteria:

  1. Age less than 18 or greater than 80 years of age
  2. refuse informed consent
  3. Co-existing valvular heart disease
  4. Acute or evolving myocardial infarction
  5. hypersensitivity to propofol or formulation component
  6. Use of NSAIDs, Vitamins C or E within 5 to 7 days of surgery

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00734383

Layout table for location information
Canada, British Columbia
UBC Dept of Anesthesiology, Pharmacology & Therapeutics, Vancouver Acute Hospital
Vancouver, British Columbia, Canada, V5Z 4E3
Sponsors and Collaborators
University of British Columbia
Canadian Institutes of Health Research (CIHR)
Layout table for investigator information
Principal Investigator: David M. Ansley, MD University of British Columbia
Study Director: Peter T. Choi, MD University of British Columbia
Study Director: David DY Chen, Ph.D University of British Columbia

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: University of British Columbia Identifier: NCT00734383     History of Changes
Other Study ID Numbers: H04-70456
First Posted: August 14, 2008    Key Record Dates
Last Update Posted: July 13, 2012
Last Verified: July 2012
Keywords provided by University of British Columbia:
coronary artery bypass surgery
coronary artery bypass grafting
cardiopulmonary bypass
myocardial injury markers,
sex differences
cardiac anesthesia
inhalational anesthetics
Additional relevant MeSH terms:
Layout table for MeSH terms
Central Nervous System Depressants
Physiological Effects of Drugs
Hypnotics and Sedatives
Anesthetics, Intravenous
Anesthetics, General